Burns and Scalds Medicine Market: Supplier Dispersion, Portfolio Width, and the Scar Management Continuity Imperative
Core keywords: burns and scalds medicine, supplier dispersion, salve formulations, scar management, hospital procurement

The global burns and scalds medicine market is projected to grow from USD 454 million in 2024 to USD 601 million by 2031, expanding at a 3.70% CAGR. For procurement leaders and hospital pharmacy decision-makers, the growth rate is not the decisive figure. The decisive figures are structural: the top five players—MEBO, B. Braun, Integra LifeSciences, Tianjin Pharmaceutical Da Ren Tang Group, and Smith & Nephew—account for 40% of market share, salves hold 53% of product demand, and hospitals and clinics represent 52% of applications. These numbers describe a market that is moderately dispersed at the supplier level, heavily weighted toward a single dosage form, and concentrated in the institutional channel. The procurement challenge is not finding a burns medicine. It is assembling a formulary that covers the full treatment pathway—from acute wound management through infection prevention to scar maturation—without relying on a single supplier whose portfolio covers only one stage. This analysis examines the clinical complexity that drives demand, the supplier dispersion that creates both optionality and fragmentation risk, and the procurement logic that separates a complete burns formulary from a collection of unrelated products.

Clinical Definition and the Procurement Relevance of Burn Severity
Burns are a common traumatic disease caused by physical or chemical factors, such as heat, chemistry, electric current, and radiation. Small-area burns only cause damage to the skin and/or mucosal tissue or the corresponding deep tissue. However, larger-area burns can cause functional, metabolic, and morphological changes in various systems of the body to varying degrees, causing severe systemic reactions and internal organ damage, and complications such as shock, sepsis, and multiple organ failure, with a high mortality rate. The healing and treatment process of burn wounds is complex and takes a long time. After the wound heals, sequelae such as scar contracture and functional impairment may remain. Therefore, burns, especially large-area burns, are the most complex and serious traumatic diseases.

For technical decision-makers, the procurement relevance lies in the severity stratification. A minor scald—a kitchen accident, a hot water spill—is treated with a topical salve and outpatient follow-up. A large-area severe burn requires specialist care, multidisciplinary consultation across general surgery, cardiothoracic surgery, urology, orthopedics, anesthesiology, and internal medicine, and a treatment pathway that spans weeks to months. The procurement question is not "what is the salve's price per tube?" It is "does the formulary cover the full severity spectrum, and does the supplier's portfolio include the products needed at each stage—antimicrobial dressings for the acute phase, debridement agents for wound bed preparation, and scar management products for the rehabilitation phase?"

Product Definition and the Three-Category Structure
Burn and scald medicines refer to medicines used to treat skin or tissue damage caused by heat (such as flames, hot water, steam), chemicals, electric current, or radiation. The main functions of these medicines are to relieve pain, prevent infection, promote wound healing, and reduce scar formation. According to the severity and type of burns, burn and scald medicines can be divided into topical medicines, oral medicines, and new therapies.

For procurement, the three-category structure is the formulary framework. Topical medicines—salves, creams, ointments, and dressings—are the volume base and the first-line treatment for most burns. Their qualification criteria center on antimicrobial efficacy, wound healing promotion, and sensory acceptability. Oral medicines—analgesics, antibiotics, and nutritional support—are adjuncts that support the patient through the systemic response to severe burns. Their qualification criteria center on systemic safety and interaction with the topical regimen. New therapies—biologic dressings, skin substitutes, and growth factor treatments—are the high-cost, high-complexity segment used for severe burns where conventional topical treatment is insufficient. Their qualification criteria center on clinical evidence and regulatory approval.

The procurement action is to map the formulary against the three categories and to identify whether the supplier's portfolio covers the categories the institution actually uses. A supplier that offers only salves is not a complete burns partner for a burn center. A supplier that offers salves, dressings, and skin substitutes is a more complete partner, even if its salve price is higher.

Market Structure: 40% Top-Five Concentration and the Dispersion Advantage
This report profiles key players of burns and scalds medicine such as MEBO, B. Braun, Integra LifeSciences, Tianjin Pharmaceutical Da Ren Tang Group Corporation, and Smith & Nephew. In 2024, the global top five players account for 40% of market share in terms of revenue.

A 40% top-five share describes a market that is moderately dispersed. Unlike the semiconductor materials markets where the top five hold 80–90%, the burns medicine market has a long tail of regional and specialty suppliers. The dispersion is sustained by the clinical diversity of burn treatment: a product that is effective for a minor scald may not be appropriate for a severe burn, and a product that is used in one country may not be registered in another. The result is a market where no single supplier can serve all geographies and all severity levels.

MEBO is the most prominent example of a supplier with a broad burns portfolio and a global presence, particularly in Asia and emerging markets. B. Braun brings a hospital supply relationship and a broad wound care portfolio. Integra LifeSciences focuses on advanced wound care and skin substitutes, positioning it in the severe-burn segment. Tianjin Pharmaceutical Da Ren Tang holds a strong position in the Chinese market. Smith & Nephew brings advanced wound management and negative pressure therapy capabilities.

For procurement, the dispersion creates optionality but also fragmentation risk. A hospital that sources from multiple suppliers for different burn treatment stages may achieve better clinical coverage but higher administrative complexity and less volume leverage. A hospital that sources from a single supplier may achieve better pricing but narrower clinical coverage. The procurement question is whether the institution's burn volume justifies the administrative cost of multi-supplier management, or whether a single-supplier portfolio approach with a broad-range supplier is the better trade-off.

Product Segmentation: Salves at 53% and the Dosage Form Concentration
In terms of product type, salve is the largest segment, holding a share of 53%.

The salve dominance reflects the clinical reality of burn treatment. A salve is easy to apply, can be used on irregular wound surfaces, and provides a moist wound healing environment that promotes re-epithelialization. It is the first-line treatment for minor and moderate burns, and it is used as an adjunct in severe burns after the acute phase. The procurement implication is that the salve segment is where the volume is, and where price competition is most intense. A supplier that competes only on salve price is competing in a commodity segment.

The remaining 47% comprises dressings, oral medicines, and new therapies. The dressings segment—antimicrobial dressings, foam dressings, and biosynthetic dressings—is where the clinical differentiation is highest. A dressing that manages exudate effectively, reduces dressing change frequency, and minimizes pain during change is worth a premium over a commodity gauze. The procurement action is to evaluate the dressing segment on clinical outcomes—dressing change frequency, infection rate, healing time—not just on unit price.

Application Concentration: Hospitals and Clinics at 52%
In terms of product application, hospitals and clinics is the largest application, holding a share of 52%.

The hospital and clinic dominance means that the burns medicine market is primarily an institutional market. The procurement dynamics are shaped by hospital formulary committees, group purchasing organizations, and clinical guidelines. The remaining 48% comprises retail pharmacy, home care, and other channels, where the patient or caregiver makes the purchase decision.

For procurement at hospitals and clinics, the 52% share means that the institution's formulary decision has a significant impact on the supplier's volume. A hospital that standardizes on a supplier's salve across its emergency department, burn unit, and outpatient clinic can negotiate volume pricing that a retail pharmacy cannot. The procurement action is to aggregate demand across departments and to negotiate a formulary agreement that covers the full treatment pathway, not just the salve.

Market Drivers and the Severe-Burn Treatment Gap
The demand for burns and scalds medicine is driven by the incidence of burns, which remains significant despite prevention efforts. The clinical complexity of severe burns—the need for multidisciplinary care, the long healing process, and the risk of scar contracture—creates demand for a range of products that address different stages of the treatment pathway.

The severe-burn treatment gap is the most consequential procurement insight in this market. The salve segment at 53% serves the high-volume, low-acuity end of the market. The severe-burn end—where skin substitutes, biologic dressings, and advanced therapies are used—is a smaller volume but a higher-value segment. A hospital that treats severe burns needs access to these advanced products, even if the volume is low, because the clinical consequences of not having them are severe. The procurement action is to ensure that the formulary includes the advanced products required for severe burns, even if they are not the volume drivers, and to negotiate access terms that reflect the low volume but high clinical necessity.

The Buyer's Action List
The market's trajectory from USD 454 million in 2024 to USD 601 million by 2031 at 3.70% CAGR describes a market where demand is steady, supply is moderately dispersed, and the clinical pathway spans multiple product categories. Three procurement actions follow.

First, map the formulary against the full treatment pathway. The 53% salve share and the 52% hospital and clinic share mean that the volume is in topical products for moderate burns. But the clinical need extends to dressings, oral medicines, and advanced therapies for severe burns. A formulary that covers only salves is incomplete for any institution that treats severe burns. Map the formulary against the acute, proliferative, and remodeling phases of burn healing, and identify gaps.

Second, evaluate suppliers on portfolio breadth and clinical evidence, not just salve price. The 40% top-five concentration means that the leading suppliers have different portfolio strengths. A supplier with a broad portfolio and clinical evidence across the treatment pathway is a more complete partner than a supplier that competes only on salve price. Request clinical evidence for the specific products the institution uses, not just the salve.

Third, negotiate access terms for low-volume, high-necessity advanced products. The severe-burn products—skin substitutes, biologic dressings—are low volume but clinically essential. A procurement strategy that focuses only on high-volume salves may leave the institution without access to advanced products when a severe burn case arrives. Negotiate access terms that reflect the low volume but high clinical necessity, including availability commitments and pricing that does not penalize low-volume ordering.

The burns and scalds medicine market rewards buyers who understand that the salve is not the procurement; the treatment pathway is. The 40% concentration is a signal that the supplier pool is dispersed enough to create optionality. The 53% salve share is a signal that the volume is in commodity topicals, but the clinical necessity extends beyond them.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp